![Koichi Morioka](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Koichi Morioka
Comptroller/Controller/Auditor bei M's Science Corp.
Ursprung des Netzwerks ersten Grades von Koichi Morioka
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Koichi Morioka
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Keio University | College/University | Undergraduate Degree Corporate Officer/Principal | |
University of Tokyo | College/University | Doctorate Degree Graduate Degree | |
Waseda University | College/University | Undergraduate Degree Undergraduate Degree | |
Academia Co. Ltd.
![]() Academia Co. Ltd. Investment ManagersFinance Academia Co. Ltd. is an independent private equity investment firm located in Tokyo, Japan. They are the investment managers of Minerva No 1 Investment LP, which owns ZK Holdings KK, their acquisition vehicle. | Investment Managers | President | |
Fujirebio, Inc.
![]() Fujirebio, Inc. Medical SpecialtiesHealth Technology Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan. | Medical Specialties | President | |
Selonterra, Inc.
![]() Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Biotechnology | Chief Executive Officer | |
NeuroAssets Sàrl | Corporate Officer/Principal | ||
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Basel | College/University | Doctorate Degree | |
Swiss Federal Institute of Technology | College/University | Undergraduate Degree | |
CHUGAI PHARMACEUTICAL CO., LTD | Pharmaceuticals: Major | Corporate Officer/Principal | |
CHORDIA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
INDEE Medical, Inc.
![]() INDEE Medical, Inc. Medical SpecialtiesHealth Technology INDEE Medical, Inc. engages in the manufacture and sale of medical related products. It distributes ReCell, a treatment kit that creates cell suspension once sprayed or applied on wounds with damage. It is also being used for scars, vitiligo, nevus, leg ulcers, and in cosmetic surgery. The company was founded in January 2016 and is headquartered in Tokyo, Japan. | Medical Specialties | Founder | |
Ortho-Clinical Diagnostics KK | Director/Board Member | ||
Quintiles Transnational Japan K.K.
![]() Quintiles Transnational Japan K.K. Pharmaceuticals: MajorHealth Technology Part of Quintiles Transnational Corp., Quintiles Transnational Japan K.K. is a Japanese company that manufactures and distributes pharmaceutical drugs and provides training services for medical professionals. The company is based in Tokyo, Japan. Yoh Narimatsu has been the CEO of the company since 2006. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AJINOMOTO CO., INC. | Food: Specialty/Candy | Corporate Officer/Principal | |
JAPAN PURE CHEMICAL CO.,LTD. | Industrial Specialties | Director/Board Member | |
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
ACUCELA INC | Pharmaceuticals: Major | Director/Board Member | |
SANTEN PHARMACEUTICAL CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
SEED CO.,LTD. | Medical Specialties | Comptroller/Controller/Auditor | |
Fujigin Capital Co., Ltd. | President | ||
ARTNATURE INC. | Consumer Sundries | Director/Board Member | |
ALCONIX CORPORATION | Metal Fabrication | Director/Board Member | |
Kyoto University | College/University | Graduate Degree |
Statistik
International
Japan | 22 |
Vereinigte Staaten | 5 |
Schweiz | 4 |
Deutschland | 2 |
Sektoral
Health Technology | 14 |
Consumer Services | 7 |
Finance | 3 |
Consumer Non-Durables | 3 |
Process Industries | 2 |
Operativ
Director/Board Member | 15 |
Corporate Officer/Principal | 9 |
President | 5 |
Comptroller/Controller/Auditor | 5 |
Undergraduate Degree | 4 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Shunji Tanefusa | 10 |
Akihiko Shimauchi | 9 |
Roman Urfer | 7 |
Shiro Mita | 6 |
Naoya Saishu | 3 |
Wakao Sato | 2 |
Tsutomu Higashide | 2 |
- Börse
- Insiders
- Koichi Morioka
- Unternehmensverbindungen